Phase 3b RCT in 378 adults with obesity after 60 weeks of tirzepatide: at week 112, weight change was −21.9% continuing maximum tolerated dose and −16.6% on 5 mg vs −9.9% switching to placebo (all p<0.0001); GI adverse events were common.
RCTn = 378
Horn et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial